Equity MRK
Friday, November 16, 2018   
Adani Ports  346.65    (0.39%)
 
Asian Paints  1320.45    (0.62%)
 
Axis Bank  618.30    (-1.17%)
 
Bajaj Auto  2696.80    (0.95%)
 
Bharti Airtel  333.60    (9.81%)
 
Coal India  263.45    (0.15%)
 
H D F C  1887.55    (1.91%)
 
HDFC Bank  1998.90    (1.26%)
 
Hero Motocorp  2954.55    (1.28%)
 
Hind. Unilever  1690.75    (-0.87%)
 
ICICI Bank  367.40    (-0.60%)
 
IndusInd Bank  1498.85    (-0.99%)
 
Infosys  650.45    (-0.90%)
 
ITC  276.25    (0.66%)
 
Kotak Mah. Ban...  1167.50    (0.42%)
 
Larsen & Toubr...  1396.00    (-0.10%)
 
M & M  767.35    (0.20%)
 
Maruti Suzuki  7332.05    (-2.02%)
 
NTPC  154.05    (0.10%)
 
O N G C  156.55    (-1.48%)
 
Power Grid Cor...  187.95    (0.40%)
 
Reliance Inds.  1127.50    (2.79%)
 
St Bk of India  290.30    (1.75%)
 
Sun Pharma.Ind...  519.60    (0.90%)
 
Tata Motors  179.40    (-0.31%)
 
Tata Motors-DV...  98.80    (0.41%)
 
Tata Steel  574.10    (-2.47%)
 
TCS  1882.25    (0.90%)
 
Vedanta  206.70    (-0.41%)
 
Wipro  325.95    (0.62%)
 
Yes Bank  191.30    (-7.14%)
 
Market Menu
plusminDaily Market Tracker
plusminNews
Corporate Information
Corporate Actions
Other Markets
Close
You are here : Equity | News | Corporate News
Cadila Healthcare's JV facility of Zydus Hopsira Oncology receives EIR from USFDA
(13:08, 12 Jul 2018)
Cadila Healthcare announced that the manufacturing facility of Zydus Hopsira Oncology, a 50:50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is closed and states that theinspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from 5 to 12 April, 2018.

Powered by Capital Market - Live News